New combo therapy aims to keep High-Risk nasopharyngeal cancer at bay
NCT ID NCT06093061
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether a year-long combination of tislelizumab (an immunotherapy) and low-dose capecitabine (a chemotherapy pill) can prevent cancer relapse in 53 patients with high-risk nasopharyngeal carcinoma. Participants have already received standard chemotherapy and radiation, but still have detectable Epstein-Barr virus DNA in their blood, indicating a higher risk of the cancer returning. The main goal is to see how many patients remain cancer-free two years after starting treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab and capecitabine
- What this could lead to
- If successful, this combination could improve disease-free survival for high-risk nasopharyngeal carcinoma patients who have a higher chance of relapse.
- What could go wrong
- This is a small, early-phase trial with only 53 participants and no comparison group, so results may not apply broadly. Side effects from the drugs are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Centre Singapore
RECRUITINGSingapore, 168583, Singapore
-
Tan Tock Seng Hospital
RECRUITINGSingapore, 308433, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers